Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients

Published:2016-03-12 Issue:16 Volume:7 Page:22257-22270
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hsu Hung-Chih¹²,Thiam Tan Kien³,Lu Yen-Jung³,Yeh Chien Yuh²⁴,Tsai Wen-Sy²⁴,You Jeng Fu²⁴,Hung Hsin Yuan²⁴,Tsai Chi-Neu⁵,Hsu An³,Chen Hua-Chien³,Chen Shu-Jen³,Yang Tsai-Sheng¹²

Affiliation:

1. Division of Hematology-Oncology, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan 333, Taiwan

2. College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 333, Taiwan

3. ACT Genomics, Neihu Dist., Taipei 114, Taiwan

4. Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan 333, Taiwan

5. Graduate Institute of Clinical Medicine, College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 333, Taiwan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Blood Serum Antagonizes Effects of EGFR/HER2-Targeted Drug Lapatinib on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Биохимия;2024-09-14

2. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review;Frontiers in Oncology;2024-08-22

3. A panorama of colon cancer in the era of liquid biopsy;The Journal of Liquid Biopsy;2024-06

4. Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis;International Journal of Molecular Sciences;2024-04-25

5. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Biochemistry (Moscow);2024-03